Chronic intestinal pseudoobstruction

Greg Lyford, Amy Foxx-Orenstein

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Patients with chronic intestinal pseudoobstruction (CIP) experience a constellation of symptoms including abdominal pain, nausea, fullness, and malaise which fluctuates in severity and invariably result in a diminished quality of life. Though surgical resection or transplantation may be an option for some, there currently is no cure for CIP. Thus, management strategies utilize pharmacologic, intravenous, endoscopic, and surgical techniques to promote transit, minimize painful bloating, reduce complications of stasis, and improve quality of life. Prokinetic agents such as erythromycin, metoclopramide, cisapride, neostigmine, and tegaserod may be effective for acute exacerbations. Octreotide may reduce symptoms of bacterial overgrowth and bloating by stimulating migrating motor complexes. Enteral tubes for venting and nutritional support may reduce hospitalizations. Total parenteral nutrition (TPN), fraught with well-known complications, may be the only tolerated source for nutrients and fluid. Advanced disease may magnify nutritional problems, difficulties of long term intravenous and intestinal access, and poor symptom control. Because the initial process may manifest in other intestinal regions following surgery, resection of involved segments should be performed with caution. Small intestinal transplantation is a high-risk surgery performed in persons unable to tolerate intravenous (IV) nutrition. Optimal management for persons with CIP should not only provide nutritional and symptom focused care but should be part of a supportive network which links patients to their appropriate healthcare needs.

Original languageEnglish (US)
Pages (from-to)317-325
Number of pages9
JournalCurrent Treatment Options in Gastroenterology
Volume7
Issue number4
StatePublished - Aug 2004

Fingerprint

Intestinal Pseudo-Obstruction
Transplantation
Quality of Life
Migrating Myoelectric Complexes
Cisapride
Neostigmine
Metoclopramide
Octreotide
Nutritional Support
Total Parenteral Nutrition
Erythromycin
Nausea
Abdominal Pain
Small Intestine
Hospitalization
Delivery of Health Care
Food

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Lyford, G., & Foxx-Orenstein, A. (2004). Chronic intestinal pseudoobstruction. Current Treatment Options in Gastroenterology, 7(4), 317-325.

Chronic intestinal pseudoobstruction. / Lyford, Greg; Foxx-Orenstein, Amy.

In: Current Treatment Options in Gastroenterology, Vol. 7, No. 4, 08.2004, p. 317-325.

Research output: Contribution to journalArticle

Lyford, G & Foxx-Orenstein, A 2004, 'Chronic intestinal pseudoobstruction', Current Treatment Options in Gastroenterology, vol. 7, no. 4, pp. 317-325.
Lyford G, Foxx-Orenstein A. Chronic intestinal pseudoobstruction. Current Treatment Options in Gastroenterology. 2004 Aug;7(4):317-325.
Lyford, Greg ; Foxx-Orenstein, Amy. / Chronic intestinal pseudoobstruction. In: Current Treatment Options in Gastroenterology. 2004 ; Vol. 7, No. 4. pp. 317-325.
@article{6324baa8734d4f51bc8802f6a3900cd0,
title = "Chronic intestinal pseudoobstruction",
abstract = "Patients with chronic intestinal pseudoobstruction (CIP) experience a constellation of symptoms including abdominal pain, nausea, fullness, and malaise which fluctuates in severity and invariably result in a diminished quality of life. Though surgical resection or transplantation may be an option for some, there currently is no cure for CIP. Thus, management strategies utilize pharmacologic, intravenous, endoscopic, and surgical techniques to promote transit, minimize painful bloating, reduce complications of stasis, and improve quality of life. Prokinetic agents such as erythromycin, metoclopramide, cisapride, neostigmine, and tegaserod may be effective for acute exacerbations. Octreotide may reduce symptoms of bacterial overgrowth and bloating by stimulating migrating motor complexes. Enteral tubes for venting and nutritional support may reduce hospitalizations. Total parenteral nutrition (TPN), fraught with well-known complications, may be the only tolerated source for nutrients and fluid. Advanced disease may magnify nutritional problems, difficulties of long term intravenous and intestinal access, and poor symptom control. Because the initial process may manifest in other intestinal regions following surgery, resection of involved segments should be performed with caution. Small intestinal transplantation is a high-risk surgery performed in persons unable to tolerate intravenous (IV) nutrition. Optimal management for persons with CIP should not only provide nutritional and symptom focused care but should be part of a supportive network which links patients to their appropriate healthcare needs.",
author = "Greg Lyford and Amy Foxx-Orenstein",
year = "2004",
month = "8",
language = "English (US)",
volume = "7",
pages = "317--325",
journal = "Current Treatment Options in Gastroenterology",
issn = "1092-8472",
publisher = "Current Science, Inc.",
number = "4",

}

TY - JOUR

T1 - Chronic intestinal pseudoobstruction

AU - Lyford, Greg

AU - Foxx-Orenstein, Amy

PY - 2004/8

Y1 - 2004/8

N2 - Patients with chronic intestinal pseudoobstruction (CIP) experience a constellation of symptoms including abdominal pain, nausea, fullness, and malaise which fluctuates in severity and invariably result in a diminished quality of life. Though surgical resection or transplantation may be an option for some, there currently is no cure for CIP. Thus, management strategies utilize pharmacologic, intravenous, endoscopic, and surgical techniques to promote transit, minimize painful bloating, reduce complications of stasis, and improve quality of life. Prokinetic agents such as erythromycin, metoclopramide, cisapride, neostigmine, and tegaserod may be effective for acute exacerbations. Octreotide may reduce symptoms of bacterial overgrowth and bloating by stimulating migrating motor complexes. Enteral tubes for venting and nutritional support may reduce hospitalizations. Total parenteral nutrition (TPN), fraught with well-known complications, may be the only tolerated source for nutrients and fluid. Advanced disease may magnify nutritional problems, difficulties of long term intravenous and intestinal access, and poor symptom control. Because the initial process may manifest in other intestinal regions following surgery, resection of involved segments should be performed with caution. Small intestinal transplantation is a high-risk surgery performed in persons unable to tolerate intravenous (IV) nutrition. Optimal management for persons with CIP should not only provide nutritional and symptom focused care but should be part of a supportive network which links patients to their appropriate healthcare needs.

AB - Patients with chronic intestinal pseudoobstruction (CIP) experience a constellation of symptoms including abdominal pain, nausea, fullness, and malaise which fluctuates in severity and invariably result in a diminished quality of life. Though surgical resection or transplantation may be an option for some, there currently is no cure for CIP. Thus, management strategies utilize pharmacologic, intravenous, endoscopic, and surgical techniques to promote transit, minimize painful bloating, reduce complications of stasis, and improve quality of life. Prokinetic agents such as erythromycin, metoclopramide, cisapride, neostigmine, and tegaserod may be effective for acute exacerbations. Octreotide may reduce symptoms of bacterial overgrowth and bloating by stimulating migrating motor complexes. Enteral tubes for venting and nutritional support may reduce hospitalizations. Total parenteral nutrition (TPN), fraught with well-known complications, may be the only tolerated source for nutrients and fluid. Advanced disease may magnify nutritional problems, difficulties of long term intravenous and intestinal access, and poor symptom control. Because the initial process may manifest in other intestinal regions following surgery, resection of involved segments should be performed with caution. Small intestinal transplantation is a high-risk surgery performed in persons unable to tolerate intravenous (IV) nutrition. Optimal management for persons with CIP should not only provide nutritional and symptom focused care but should be part of a supportive network which links patients to their appropriate healthcare needs.

UR - http://www.scopus.com/inward/record.url?scp=4344678133&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4344678133&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:4344678133

VL - 7

SP - 317

EP - 325

JO - Current Treatment Options in Gastroenterology

JF - Current Treatment Options in Gastroenterology

SN - 1092-8472

IS - 4

ER -